CoChat

The PEA3 Ets Transcription Factor Comprises Multiple Domains That Regulate Transactivation and DNA Binding

Open access
Bojović, Bojana Bonnie, Hassell, John A. · 2001 · Journal of Biological Chemistry

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

Abstract

PEA3, a member of the Ets family of transcription factors, is a nuclear phosphoprotein capable of activating transcription. Mouse PEA3 comprises 480 amino acids and bears an approximately 85-amino acid ETS domain near its carboxyl terminus. Whereas analyses of bacterially expressed PEA3 revealed that the ETS domain is required for sequence-specific DNA binding, little is known of the functional domains in the protein required for its activity in mammalian cells. To this end, we defined the location of the PEA3 functional domains in COS cells. PEA3 bears a strong activation domain near its amino terminus, which is flanked by two regions that independently negatively regulate its activity. PEA3 expressed in COS cells was incapable of binding to DNA in vitro. However, DNA binding activity could be unmasked by incubation with a PEA3-specific antibody. Analyses of the DNA binding activity of PEA3 deletion mutants revealed that two regions flanking the ETS domain independently inhibited DNA binding; deletion of both regions was required to detect DNA binding in the absence of a PEA3-specific antibody. Under these conditions, the ETS domain was sufficient for sequence-specific DNA binding. These findings suggest that the activity of PEA3 is exquisitely controlled at multiple functional levels.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1074/jbc.m005509200

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIG. 1 Identification of regions in PEA3 affecting its transcriptional activity in COS cells. A , schematic illustrating the structure of WT PEA3 and deletion derivatives thereof. B , comparative expression level and specific activity of the deletion mutants. The transcriptional activity and expression level of WT PEA3 was set at 100%. The data were derived from four independent experiments. C , representative immunoblot illustrating the abundance of PEA3 and amino-terminal deletion mutants thereof in equal amounts (20 m g) of total cell protein from transfected COS cells. Lane 1 , lysate from COS cells transfected with 0.8 m g of the empty expression vector, pRC/RSV. Lanes 2-5 , COS cell lysate from cells transfected with 0.2, 0.4, 0.6, or 0.8 m g of pRC/RSV-PEA3 encoding WT PEA3. Lanes 6-17 , lysate from COS cells transfected with 0.8 m g of pRC/RSV-PEA3 encoding the amino-terminal deletion mutants, D N45, D N55, D N65, D N74, D N85, D N106, D N120, D N130, D N145, D N226, D N245, and D N326, respectively. The polyclonal antibody, PC2, was used to detect PEA3 and its derivatives in these samples. Note the occurrence of a cellular cross-reacting protein in all the lanes that migrates between the 48- and 34-kDa markers. D , representative immunoblot showing the abundance of PEA3 and PEA3 deletion mutants in equal amounts (20 m g) of total cell protein from transfected COS cells. Lane 18 , lysate from COS cells transfected with 0.8 m g of the empty expression vector, pRC/RSV. Lanes 19-21 , COS cell lysate from cells transfected with 0.2, 0.4, or 0.8 m g of pRC/RSV-PEA3 encoding WT PEA3, respectively. Lanes 22-26 , lysate from COS cells transfected with 0.8 m g of pRC/RSV-PEA3 encoding D N29, D C420, D C430, D C440, and D C450, respectively. The monoclonal antibody, MP16, was used to detect PEA3 and its deleted derivatives in these samples.
FIG. 1 Identification of regions in PEA3 affecting its transcriptional activity in COS cells. A , schematic illustrating the structure of WT PEA3 and deletion derivatives thereof. B , comparative expression level and specific activity of the deletion mutants. The transcriptional activity and expression level of WT PEA3 was set at 100%. The data were derived from four independent experiments. C , representative immunoblot illustrating the abundance of PEA3 and amino-terminal deletion mutants thereof in equal amounts (20 m g) of total cell protein from transfected COS cells. Lane 1 , lysate from COS cells transfected with 0.8 m g of the empty expression vector, pRC/RSV. Lanes 2-5 , COS cell lysate from cells transfected with 0.2, 0.4, 0.6, or 0.8 m g of pRC/RSV-PEA3 encoding WT PEA3. Lanes 6-17 , lysate from COS cells transfected with 0.8 m g of pRC/RSV-PEA3 encoding the amino-terminal deletion mutants, D N45, D N55, D N65, D N74, D N85, D N106, D N120, D N130, D N145, D N226, D N245, and D N326, respectively. The polyclonal antibody, PC2, was used to detect PEA3 and its derivatives in these samples. Note the occurrence of a cellular cross-reacting protein in all the lanes that migrates between the 48- and 34-kDa markers. D , representative immunoblot showing the abundance of PEA3 and PEA3 deletion mutants in equal amounts (20 m g) of total cell protein from transfected COS cells. Lane 18 , lysate from COS cells transfected with 0.8 m g of the empty expression vector, pRC/RSV. Lanes 19-21 , COS cell lysate from cells transfected with 0.2, 0.4, or 0.8 m g of pRC/RSV-PEA3 encoding WT PEA3, respectively. Lanes 22-26 , lysate from COS cells transfected with 0.8 m g of pRC/RSV-PEA3 encoding D N29, D C420, D C430, D C440, and D C450, respectively. The monoclonal antibody, MP16, was used to detect PEA3 and its deleted derivatives in these samples.CC-BY-NC-ND · From the PDF
FIG. 2 Transcriptional activity of GAL4-PEA3 chimeras. A , schematic illustrating the structure of the GAL4-PEA3 chimeras. Each chimera bears the GAL4 DNA binding domain and either all of PEA3 or various amino-terminal portions of PEA3. The abundance (relative expression) of the various GAL4-PEA3 chimeras relative to that of GAL4-PEA3dlC85 ( D C85), which was set as 1.0, is shown. Similarly, the specific activity of the GAL4-PEA3 chimeras by comparison with that of GAL4-PEA3dlC85 is also shown. The data from four independent experiments were averaged. B , representative immunoblot of the abundance of the GAL4-PEA3 chimeras in COS cell lysates resulting from a single experiment. Equal amounts of total cellular protein (30 m g) was loaded onto the gel prior to immunoblotting. Protein samples were prepared from COS cells transfected with 0.5 m g of the pSG424-PEA3 expression vectors encoding D C317 ( lane 1 ), D C267 ( lane 2 ), D C177 ( lane 3 ), D C128 ( lane 4 ), D C120 ( lane 5 ), D C85 ( lane 6 ), D C55 ( lane 7 ), and GAL4-PEA3 ( lane 8 ). The GAL4-PEA3 chimeras were detected with an antibody that recognizes determinants in the GAL4 DNA binding domain.
FIG. 2 Transcriptional activity of GAL4-PEA3 chimeras. A , schematic illustrating the structure of the GAL4-PEA3 chimeras. Each chimera bears the GAL4 DNA binding domain and either all of PEA3 or various amino-terminal portions of PEA3. The abundance (relative expression) of the various GAL4-PEA3 chimeras relative to that of GAL4-PEA3dlC85 ( D C85), which was set as 1.0, is shown. Similarly, the specific activity of the GAL4-PEA3 chimeras by comparison with that of GAL4-PEA3dlC85 is also shown. The data from four independent experiments were averaged. B , representative immunoblot of the abundance of the GAL4-PEA3 chimeras in COS cell lysates resulting from a single experiment. Equal amounts of total cellular protein (30 m g) was loaded onto the gel prior to immunoblotting. Protein samples were prepared from COS cells transfected with 0.5 m g of the pSG424-PEA3 expression vectors encoding D C317 ( lane 1 ), D C267 ( lane 2 ), D C177 ( lane 3 ), D C128 ( lane 4 ), D C120 ( lane 5 ), D C85 ( lane 6 ), D C55 ( lane 7 ), and GAL4-PEA3 ( lane 8 ). The GAL4-PEA3 chimeras were detected with an antibody that recognizes determinants in the GAL4 DNA binding domain.CC-BY-NC-ND · From the PDF
Image 3
CC-BY-NC-ND · From the PDF
FIG. 4 Mapping the borders of two negative regulatory regions flanking the amino-terminal activation domain of PEA3. A and C , schematic representations of GAL4-PEA3 chimeras. The abundance and specific activity of these chimeras were determined as described in the legend to Fig. 3. The data from four independent experiments were averaged. B and D , representative immunoblots illustrating the abundance of the various GAL4-PEA3 chimeras in COS cells. Note that the photographs were derived by splicing groups of lanes from the same individual autoradiograms. A thin white area was left between the lanes to clearly illustrate this fact. The GAL4-PEA3 chimeras were detected as described in the legend to Fig. 3.
FIG. 4 Mapping the borders of two negative regulatory regions flanking the amino-terminal activation domain of PEA3. A and C , schematic representations of GAL4-PEA3 chimeras. The abundance and specific activity of these chimeras were determined as described in the legend to Fig. 3. The data from four independent experiments were averaged. B and D , representative immunoblots illustrating the abundance of the various GAL4-PEA3 chimeras in COS cells. Note that the photographs were derived by splicing groups of lanes from the same individual autoradiograms. A thin white area was left between the lanes to clearly illustrate this fact. The GAL4-PEA3 chimeras were detected as described in the legend to Fig. 3.CC-BY-NC-ND · From the PDF
Image 5
CC-BY-NC-ND · From the PDF
FIG. 6 The cryptic DNA binding function of PEA3 is unveiled by incubation with PEA3-specific antibodies. DNA binding reactions were carried out as described under 'Experimental Procedures' using 5 m g of nuclear extracts isolated from COS-1 cells transfected with the empty expression vector ( 2 PEA3 ) or that encoding PEA3 ( 1 PEA3 ). The arrows indicate the position of protein-DNA complexes. A , antibody-PEA3-DNA complexes; B, protein-DNA complexes formed between a nuclear protein endogenous to COS cells and the PEA3 binding site; C , the free labeled DNA bearing an optimal PEA3 binding site. MP16 and PC2 refer to a monoclonal and polyclonal antibodies ( Ab ), respectively, that were preincubated with nuclear lysates before the DNA binding assays were carried out. Each of these antibodies binds to different antigenic determinants in PEA3. Myc refers to an antibody reactive with the c-Myc protein and was used as a negative control in these experiments.
FIG. 6 The cryptic DNA binding function of PEA3 is unveiled by incubation with PEA3-specific antibodies. DNA binding reactions were carried out as described under 'Experimental Procedures' using 5 m g of nuclear extracts isolated from COS-1 cells transfected with the empty expression vector ( 2 PEA3 ) or that encoding PEA3 ( 1 PEA3 ). The arrows indicate the position of protein-DNA complexes. A , antibody-PEA3-DNA complexes; B, protein-DNA complexes formed between a nuclear protein endogenous to COS cells and the PEA3 binding site; C , the free labeled DNA bearing an optimal PEA3 binding site. MP16 and PC2 refer to a monoclonal and polyclonal antibodies ( Ab ), respectively, that were preincubated with nuclear lysates before the DNA binding assays were carried out. Each of these antibodies binds to different antigenic determinants in PEA3. Myc refers to an antibody reactive with the c-Myc protein and was used as a negative control in these experiments.CC-BY-NC-ND · From the PDF
Image 7
CC-BY-NC-ND · From the PDF
Image 8
CC-BY-NC-ND · From the PDF
FIG. 8 Analyses of the DNA binding activity of amino-terminal deletion mutants. A-C , EMSA ( top panel ) and accompanying immunoblot (corresponding bottom panel ) illustrating the DNA binding activity and abundance of the amino-terminal PEA3 deletion mutants. The data illustrated in each panel were derived from a separate experiment. 5 m g of nuclear extract from transfected COS cells was used in binding reactions in the presence of the PC2 polyclonal antibody. 8 m g of nuclear extracts was used with the PC2 polyclonal antibody to detect PEA3 in the nuclear lysates by immunoblotting. D , schematic representation of PEA3 deletion derivatives that were used in these analyses. E , illustration of the DNA binding activity, expression levels and calculated specific DNA binding activity of PEA3 and its amino-terminal deletion derivatives. The specific DNAbinding activity of PEA3 or its derivatives was calculated from the total DNA binding activity present in 5.0 m g of nuclear extract and dividing by the relative amount of PEA3 as determined by immunoblotting in these extracts as described under 'Experimental Procedures.' The values shown represent the average of four independent experiments.
FIG. 8 Analyses of the DNA binding activity of amino-terminal deletion mutants. A-C , EMSA ( top panel ) and accompanying immunoblot (corresponding bottom panel ) illustrating the DNA binding activity and abundance of the amino-terminal PEA3 deletion mutants. The data illustrated in each panel were derived from a separate experiment. 5 m g of nuclear extract from transfected COS cells was used in binding reactions in the presence of the PC2 polyclonal antibody. 8 m g of nuclear extracts was used with the PC2 polyclonal antibody to detect PEA3 in the nuclear lysates by immunoblotting. D , schematic representation of PEA3 deletion derivatives that were used in these analyses. E , illustration of the DNA binding activity, expression levels and calculated specific DNA binding activity of PEA3 and its amino-terminal deletion derivatives. The specific DNAbinding activity of PEA3 or its derivatives was calculated from the total DNA binding activity present in 5.0 m g of nuclear extract and dividing by the relative amount of PEA3 as determined by immunoblotting in these extracts as described under 'Experimental Procedures.' The values shown represent the average of four independent experiments.CC-BY-NC-ND · From the PDF
FIG. 10 Deletion of both inhibitory regions flanking the PEA3 ETS domain relieves the requirement for a cross-reacting antibody for DNA binding. Duplicate samples of nuclear extract (5 m g) from independently transfected COS cells were analyzed. The PC2 polyclonal antibody was added where indicated. The arrows indicate specific PEA3-DNA complexes ( A and C ), the protein-DNA complex due to the binding of an endogenous protein in COS cell nuclear extracts ( B ), and the free PEA3 double-stranded oligonucleotide used in the assay ( D ). The schematic depicts the structure of PEA3 and the PEA3 D N315 D C417 deletion mutant, which harbors only the ETS domain.
FIG. 10 Deletion of both inhibitory regions flanking the PEA3 ETS domain relieves the requirement for a cross-reacting antibody for DNA binding. Duplicate samples of nuclear extract (5 m g) from independently transfected COS cells were analyzed. The PC2 polyclonal antibody was added where indicated. The arrows indicate specific PEA3-DNA complexes ( A and C ), the protein-DNA complex due to the binding of an endogenous protein in COS cell nuclear extracts ( B ), and the free PEA3 double-stranded oligonucleotide used in the assay ( D ). The schematic depicts the structure of PEA3 and the PEA3 D N315 D C417 deletion mutant, which harbors only the ETS domain.CC-BY-NC-ND · From the PDF
FIG. 9 Analysis of the DNA binding activity of C-terminal deletion mutants of PEA3. A , EMSA assay of the indicated mutants. 8 m g of nuclear extracts from transfected COS cells was used with the MP16 monoclonal antibody. B , immunoblot illustrating the abundance of PEA3 and the PEA3 deletion mutants in nuclear lysates from transfected COS cells. The abundance of PEA3 was assessed with the PN1 polyclonal antibody. C , schematic representation of the PEA3 deletion mutants. D , DNA binding activity, abundance, and specific DNA binding activity of the PEA3 C-terminal deletion mutants. The results represent the average of four independent experiments.
FIG. 9 Analysis of the DNA binding activity of C-terminal deletion mutants of PEA3. A , EMSA assay of the indicated mutants. 8 m g of nuclear extracts from transfected COS cells was used with the MP16 monoclonal antibody. B , immunoblot illustrating the abundance of PEA3 and the PEA3 deletion mutants in nuclear lysates from transfected COS cells. The abundance of PEA3 was assessed with the PN1 polyclonal antibody. C , schematic representation of the PEA3 deletion mutants. D , DNA binding activity, abundance, and specific DNA binding activity of the PEA3 C-terminal deletion mutants. The results represent the average of four independent experiments.CC-BY-NC-ND · From the PDF
FIG. 12 Schematic illustrating the functional domains, negative regulatory regions, and sequence motifs in mouse PEA3. AD , acidic domain; ETS , ETS domain.
FIG. 12 Schematic illustrating the functional domains, negative regulatory regions, and sequence motifs in mouse PEA3. AD , acidic domain; ETS , ETS domain.CC-BY-NC-ND · From the PDF

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 9

  1. Jeon, I. S., Davis, J. N., Braun, B. S., Sublett, J. E., Roussel, M. F., Denny, C. T., and Shapiro, D. N. (1995) Oncogene 10, 1229 -1234
  2. Monte, D., Coutte, L., Baert, J. L., Angeli, I., Stehelin, D., and de Launoit, Y. (1995) Oncogene 11, 771-779
  3. Monte, D., Baert, J. L., Defossez, P. A., de Launoit, Y., and Stehelin, D. (1994) Oncogene 9, 1397-1406
  4. Trimble, M. S., Xin, J. H., Guy, C. T., Muller, W. J., and Hassell, J. A. (1993) Oncogene 8, 3037-3042
  5. Bailly, R. A., Bosselut, R., Zucman, J., Cormier, F., Delattre, O., Roussel, M., Thomas, G., and Ghysdael, J. (1994) Mol. Cell. Biol. 14, 3230 -3241
  6. May, W. A., Lessnick, S. L., Braun, B. S., Klemsz, M., Lewis, B. C., Lunsford, L. B., Hromas, R., and Denny, C. T. (1993) Mol. Cell. Biol. 13, 7393-7398
  7. Lessnick, S. L., Braun, B. S., Denny, C. T., and May, W. A. (1995) Oncogene 10, 423-431
  8. Laget, M. P., Defossez, P. A., Albagli, O., Baert, J. L., Dewitte, F., Stehelin, D., and de Launoit, Y. (1996) Oncogene 12, 1325-1336
  9. Janknecht, R., Zinck, R., Ernst, W. H., and Nordheim, A. (1994) Oncogene 9, 1273-1278

Cited by

See all 68

Metadata

Authors
Bojović, B. B., & Hassell, J. A.
Affiliations
McMaster University (CA)
Corresponding author
Hassell, John A.
Venue
Journal of Biological Chemistry
Publisher
Elsevier BV
Published
2001-02
Volume
276
Issue
6
Pages
4509-4521
ISSN
0021-9258 (ISSN-L)
OpenAlex
W2076111240
Cited by
68
References
41
Citations by year
2023: 1 · 2022: 1 · 2020: 2 · 2018: 2 · 2017: 3 · 2016: 1 · 2015: 2 · 2014: 4 · 2013: 2 · 2012: 4
FWCI
2.54
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Biological Chemistry (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Radboud Repository (Radboud University) (submittedVersion)
  • TSpace (University of Toronto) (submittedVersion)
  • Radboud Repository (Radboud University) (submittedVersion, other-oa)
Funders
  • Canadian Institutes of Health Research
  • National Cancer Institute
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Structure and Dynamics
Keywords
PEA3, ETS transcription factors, ETS domain, functional domains, transcriptional activation, DNA binding, transactivation domain, negative regulation, deletion mutants, transcriptional regulation
MeSH terms
Animals, Base Sequence, DNA, DNA-Binding Proteins, Fungal Proteins, Protein Binding, Recombinant Fusion Proteins, Transcription Factors, Transcriptional Activation, Mutagenesis, Sequence Deletion, DNA Primers, COS Cells, Saccharomyces cerevisiae Proteins, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.